Clinical trials: Risk
Schizophrenia, Metabolic Syndrome X
Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with…
- Conditions
- Schizophrenia, Metabolic Syndrome X, Insulin Resistance
- Trial name
- NCT00338949
- Testing
- Switch, Control
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Veterans Medical Research Foundation
Leukemia, Erythroblastic, Acute, Myelodysplastic Syndromes
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
The purpose of this study is to determine whether 5-Azacytidine priming before the conditioning regimen for subjects receiving a hematopoietic stem cell transplant is an effective treatment for high risk myeloid malignancies in…
- Trial name
- NCT02497404
- Testing
- 5-Azacytidine, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Weill Medical College of Cornell University
Cardiovascular Diseases
The LEARN Study for CVD Prevention
The investigator is testing a virtual environment (VE) to address prevention of HIV-related comorbidities.
- Trial name
- LEARN (NCT05242952)
- Testing
- Gaming in a virtual environment
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Yale University
Cardiovascular Diseases
Cardiovascular Disease Population Risk Tool
The purpose of this study is to develop, evaluate, and apply a predictive algorithm for assessing CVD risk in the community setting: the Cardiovascular Disease Population Risk Tool (CVDPoRT).
- Trial name
- CVDPoRT (NCT02267447)
- Volunteers
- 104,219 people, healthy volunteers welcome
- Sponsor
- Ottawa Hospital Research Institute
Astrocytoma, Grade II, Astrocytoma, Grade III
FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma
This is a phase 2, multi-institutional, historically-controlled, study of 100 patients with newly diagnosed Grade II and III astrocytoma comparing the combination of TTFields with adjuvant temozolomide versus temozolomide alone…
- Trial name
- FORWARD (NCT03906448)
- Testing
- TTFields with adjuvant temozolomide
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Florida
Osteoporosis, Breast Cancer
Effects of Exemestane on Bone Strength
The NCIC CTG was conducting an international breast cancer prevention trial (MAP.3) examining the effects of a new therapy (exemestane) for breast cancer prevention in postmenopausal women at increased risk of developing this…
- Trial name
- MAP3BSS (NCT01144468)
- Where
- 4 sites in United States, Canada
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Anaplastic Medulloblastoma, Medulloblastoma
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
This phase III trial studies different chemotherapy and radiation therapy regimens to compare how well they work in treating young patients with newly diagnosed, previously untreated, high-risk medulloblastoma.
- Trial name
- NCT00392327
- Testing
- Biospecimen Collection, Carboplatin, Cisplatin
- Where
- 185 sites in United States, Australia and 3 more
- Volunteers
- 379 people
- Sponsor
- Children's Oncology Group
Recurrent Miscarriage, Spontaneous Abortion
Low Plasma Mannose Binding Lectin (p-MBL) Level is a Risk Factor for Recurrent Pregnancy Loss (RPL)
The present study is based on the hypothesis, that recurrent pregnancy loss (RPL) is associated with abnormal plasma mannose binding lectin (p-MBL) level.
- Conditions
- Recurrent Miscarriage, Spontaneous Abortion, Mannose-Binding Lectin Deficiency, Habitual Abortion
- Trial name
- NCT04017754
- Where
- Denmark
- Volunteers
- 452 people
- Sponsor
- Aalborg University Hospital
Eating Disorders, Female Athlete Triad
Efficacy of the Female Athlete Body Project (FAB)
Given the cost of treating eating disorders and the substantial morbidity and mortality associated with these disorders, prevention of eating disorders has considerable public health significance.
- Trial name
- FAB (NCT01735994)
- Testing
- Healthy Weight, Brochure
- Where
- United States
- Volunteers
- 481 people, healthy volunteers welcome
- Sponsor
- Pennington Biomedical Research Center
Peripheral Artery Disease
A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease
The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.
- Trial name
- EUCLID (NCT01732822)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 776 sites in United States, Argentina and 26 more
- Volunteers
- 13,885 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
This trial is conducted globally. The aim of this trial is to compare cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events.
- Trial name
- DEVOTE (NCT01959529)
- Testing
- insulin degludec, insulin glargine
- Where
- 446 sites in United States, Algeria and 18 more
- Volunteers
- 7,637 people
- Sponsor
- Novo Nordisk A/S
Deep Vein Thrombosis, Pulmonary Embolism
Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
Design: U.S.-based, single-center, randomized placebo-controlled trial. Brief Treatment Description: Low-intensity apixaban (2.5mg twice daily) for extended-duration secondary prevention of VTE after initial treatment for…
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- HI-PRO (NCT04168203)
- Testing
- Apixaban 2.5 MG
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Brigham and Women's Hospital
Rheumatoid Arthritis
Weight Loss and Exercise To Improve Rheumatoid Arthritis Cardiovascular Risk
This is a small exploratory, randomized, controlled trial. Twenty-six older (ages 60-80 yr.), obese (BMI 28-40 kg/m2) persons with rheumatoid arthritis (RA) (seropositive or erosive) will be randomized to 16 weeks of a counseling…
- Trial name
- SWET/CHAT (NCT04356183)
- Testing
- SWET: Supervised Weight loss and Exercise Training, CHAT: Counseling Health As Treatment
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Obesity, Cardiovascular Disease
Effectiveness of Four Popular Diet Strategies for Weight Loss and Cardiac Risk Reduction
A single-center randomized trial at an academic medical center in Boston, Mass, of overweight or obese adults with known hypertension, dyslipidemia, or fasting hyperglycemia.
- Conditions
- Obesity, Cardiovascular Disease, Metabolic Syndrome
- Trial name
- NCT02454127
- Testing
- Atkins Diet, Zone Diet, Weight Watchers Diet
- Volunteers
- 160 people
- Sponsor
- Tufts Medical Center
Depression, Obesity
Research Aimed at Improving Both Mood and Weight
The RAINBOW study is an NIH R01-funded randomized controlled trial to evaluate the clinical and cost effectiveness and implementation potential of a primary care integrated multicondition intervention program to help improve mood…
- Trial name
- RAINBOW-ENGAGE (NCT02246413)
- Testing
- RAINBOW Intervention Program
- Where
- 2 sites in United States
- Volunteers
- 409 people
- Sponsor
- Palo Alto Medical Foundation
Cytomegalovirus Infection
CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")
This is a trial of preemptive therapy vs. prophylaxis for prevention of Cytomegalovirus (CMV) disease in R-D+ liver transplant patients.
- Trial name
- NCT01552369
- Testing
- Valganciclovir
- Where
- 6 sites in United States
- Volunteers
- 205 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pediatric Obesity, Nutrition Disorders
The Intersection Between Loss of Control Eating and Obesity: The Role of Restriction and Food Reinforcement
This study aims to determine the relationships among loss of control eating, restriction, relative reinforcing value of high energy-dense food, and obesity risk.
- Conditions
- Pediatric Obesity, Nutrition Disorders, Binge Eating, Body Weight
- Trial name
- NCT05177705
- Testing
- Restricted access task, Structured Intake
- Where
- United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo
Symptomatic Severe Aortic Stenosis
Portico Next Generation Approval Study
The purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Navitor (Portico™ NG) Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the…
- Trial name
- NCT04011722
- Testing
- Portico™ NG (Navitor) Valve and FlexNav™ Delivery System, Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System
- Where
- 28 sites in United States, Australia and 3 more
- Volunteers
- 333 people
- Sponsor
- Abbott Medical Devices
Influenza
Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of 600 mg IV peramivir in the treatment of elderly subjects with acute uncomplicated influenza infection and in subjects with acute…
- Trial name
- NCT02635724
- Testing
- Peramivir
- Where
- 15 sites in United States
- Volunteers
- 74 people
- Sponsor
- BioCryst Pharmaceuticals